Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nordion Appoints Mr. Grant Gardiner as SVP and General Counsel

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
Mr. Gardiner will serve as the Corporation's legal officer responsible for all global legal matters, effective March 18, 2013.

"We are very pleased to welcome Grant to the Nordion management team. With more than 19 years of experience, Grant is a seasoned lawyer with a strong understanding of business and global market dynamics. His proven expertise in leading cross-listed, publicly traded companies through complex legal, governance and compliance landscapes with a business focus will be a significant asset to Nordion,” said Mr. Steve West, Chief Executive Officer, Nordion Inc. “Grant is expected to play an instrumental role in the execution of our business strategy globally.”

Mr. Gardiner joins Nordion from Research in Motion Limited (RIM) where he currently serves as Vice-President, Associate General Counsel and acted as Corporate Secretary to RIM’s Board of Directors for approximately four years. During his tenure at RIM, which began in 2008, Grant has advised on securities matters, mergers & acquisitions, ethics and compliance programs as well as Board and Corporate Governance matters.

With leadership roles at other leading global, publicly-traded companies such as Cognos Inc. (now IBM) and JDS Uniphase, Mr. Gardiner’s experience includes mergers and acquisitions, corporate governance, commercial transactions, as well as securities and anti-corruption law. He holds a Bachelor of Business Administration from the University of Prince Edward Island (1988), an L.L.B. from Osgoode Hall Law School (1991) and was admitted to the Ontario Bar in 1993.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!